The MHRA has authorised Foundayo - Eli Lilly's once-daily oral GLP-1 treatment - for UK adults with a BMI of 30 or above, or a BMI of 27 to 30 alongside at least one weight-related health condition. It is also licensed separately for improving blood sugar control in type 2 diabetes not adequately managed on existing treatment. The UK is the first European country to license the drug, which was FDA-approved in the United States in April 2026.
Unlike injectable GLP-1 treatments, Foundayo requires no needle, no refrigeration and no timing restrictions around food or water - it can be taken at any point in the day. In clinical trials it produced average weight loss of around 27 pounds on the highest dose, according to Lilly's ATTAIN-1 trial data. NICE assessment is expected in November, which will determine whether Foundayo enters NHS provision or remains private-pay for the foreseeable future. No UK price or NHS launch date has been confirmed by Lilly.
On the health insurance side, Vitality's existing tie-up with Boots - which gives qualifying members discounted access to a GLP-1 weight-loss service - has already demonstrated that at least one major insurer sees subsidising the drug now as preferable to absorbing diabetes and cardiovascular claims later. An oral, non-refrigerated GLP-1 at accessible price points changes the accessibility calculation further, and is likely to make the employer-paid and PMI-included GLP-1 conversation more common, not less.
The life insurance and group risk angle is the one that has received less attention, and it is where brokers advising clients on protection products face the most immediate practical issue.
GLP-1 use matters to life and critical illness underwriters for two distinct reasons that can cut in opposite directions. In type 2 diabetes, GLP-1 treatment is both a disclosable condition marker and, increasingly, a positive mortality signal - the underlying diagnosis is relevant, but treatment adherence indicates active management. In obesity without diabetes, the picture is less settled. Cardiovascular outcomes trials for injectable GLP-1s have shown meaningful reductions in major cardiac events in high-risk patients, but orforglipron - the active ingredient in Foundayo - does not yet have published cardiovascular outcomes trial data, and brokers should be careful not to attribute injectable GLP-1 cardiovascular findings directly to the oral drug until that data exists.
What the oral format changes is verifiability. A patient on Mounjaro or Wegovy typically has a dispensing and administration record that is difficult to conceal and straightforward to confirm at the point of underwriting. A once-daily pill, dispensed via pharmacy with no injection record and no requirement for clinical administration, leaves a far thinner paper trail. The Institute and Faculty of Actuaries flagged in its 2025 working paper on GLP-1 drugs and mortality that non-disclosure of weight-loss medication use represents an emerging and underpriced risk in life and protection underwriting, as applicants who have achieved significant weight loss through GLP-1 treatment may present at application without the treatment history being volunteered or detected.
The risk is not theoretical. A client who has lost 30 pounds via Foundayo, stopped taking it six months before applying for life cover, and presents at a significantly lower BMI than their baseline has materially changed their risk profile in ways a standard health declaration will not capture unless the insurer specifically asks about GLP-1 use - a question that many application forms, written before oral GLP-1s were commercially available in the UK, do not yet include.
For brokers placing group life, group critical illness and PMI schemes, Foundayo's UK launch creates two specific conversations worth having with employer clients and their HR teams before the next renewal.
The first is whether the group scheme's medical underwriting and enrolment processes have been updated to capture GLP-1 use as a declared item - not because the drug is necessarily adverse, but because its use, discontinuation, and any associated weight fluctuation are material to accurate risk assessment. An HR team that does not prompt disclosure of GLP-1 treatment during enrolment is creating an information gap the underwriter cannot price.
The second is whether individual protection clients - particularly those whose weight has changed significantly in the past 12 to 24 months - have been asked about GLP-1 use as part of their fact-find. The oral format makes this a wider population question than injectable treatments alone would suggest: at $149 a month at cash price in the US and with NHS assessment imminent in the UK, the potential user base is considerably broader than the clinical population currently on injectables.
